FDA increases risk level of granola bar recall due to ‘adverse health' effects
The U.S. Food and Drug Administration (FDA) has elevated the risk of a recall of various granola bars.
In its latest weekly update, the FDA shared the update about a recalled batch of MadeGood granola bars, first issued in December. According to a press release shared by MadeGood at the time, the product was recalled due to 'a very small risk' that some of the granola bar products made between January and November 2024 'may contain a piece of metal.'
The recall is now considered a 'Class II' one, meaning it is a 'situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote,' as noted by the FDA.
The products identified under the Class II recall include MadeGood's Chocolate Chip Granola Bars, which were different ounces per bar. The MadeGood Variety pack granola bars are also a part of this updated recall.
Riverside Natural Inc. first announced the recall in a press release, shared by the FDA, in December. Some of the other affected products included: Mixed Berry Granola Bars, Strawberry Granola Bars, Cookies & Crème Granola Bars, Chocolate Banana Granola Bars, and Chocolate Drizzled Birthday Cake Granola Bars.
The voluntary recall was due to the 'potential presence of a piece of metal in the product,' which 'may result in a safety hazard' if the granola bars were consumed. However, there haven't been any reported injuries due to the product.
Riverside issued the recall after conducting an extensive investigation of 'where the recalled products were manufactured and identified the source of the issue in the manufacturing process.'
The press release showed a list of the recalled products, which can be identified by the Best by Date and UPC number. You can see the list of affected granola bars here.
There's been a range of other nationwide food recalls throughout 2025. Earlier this month, 2,0176,614 cases of different baked goods from FGF, LLC were recalled due to the 'potential for contamination with listeria monocytogenes.' Some of the recalled treats range from cake donut rings, raspberry-filled donuts, french crullers, bavarian-filled donuts, Dunkin' Donuts products, including two of its munchkin flavors, and more.
As noted by the Centers for Disease Control and Prevention (CDC), listeria is a 'bacteria that can contaminate many foods. Although symptoms can vary, a listeria infection 'can cause invasive illness and intestinal illness.
The voluntary recall from FGF, LLC affects all baked goods 'within expiration produced 12/13/24 and prior.'
Union Seafoods also recently announced a voluntary recall of select canned tuna products sold under the Genova, Van Camp's, H-E-B, and Trader Joe's brands. These products were distributed nationwide at retailers such as Walmart, Trader Joe's, Costco, Kroger, and Publix.
According to the press release, Tri-Union Seafoods initiated the recall after its supplier discovered a manufacturing defect in the tuna cans' 'easy open' lids. The defect could 'compromise the integrity of the product seal (especially over time), causing it to leak, or worse, be contaminated with clostridium botulinum,' a bacteria that causes foodborne botulism and can be fatal
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Alligator Bioscience Receives FDA Endorsement of Mitazalimab Phase 3 Dose for Pancreatic Cancer
LUND, SE / / June 13, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has provided feedback supporting the selection of the 900 µg/kg dose of its CD40 agonist mitazalimab for the planned Phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC). This positive regulatory feedback confirms Alligator's dose selection and represents a key milestone in the late-stage development of mitazalimab. "We are very pleased with the FDA's timely and constructive response. This marks an important step forward as we finalize our Phase 3 program for mitazalimab in one of the most aggressive and underserved cancers. We are now in active partnering dialogues aiming to secure the right partner to take mitazalimab into Phase 3," said Søren Bregenholt, CEO of Alligator Bioscience . For further information, please contact: Søren Bregenholt, CEOE-mail: +46 (0) 46 540 82 00 The information was submitted for publication, through the agency of the contact person set out above, at 8:45 a.m. CEST on 13 June 2025. About Alligator Bioscience Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company's lead drug candidate mitazalimab is currently in preparation for Phase 3 development, and has previously presented unprecedented survival data at 24-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1. Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden. For more information, please visit . Attachments Alligator Bioscience receives FDA endorsement of mitazalimab Phase 3 dose for pancreatic cancer SOURCE: Alligator Bioscience View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Insider
an hour ago
- Business Insider
Moderna receives FDA approval for RSV vaccine
The company states: 'Moderna (MRNA) announced that the FDA has approved mRESVIA, or mRNA-1345, the company's respiratory syncytial virus, RSV, vaccine, for the prevention of lower respiratory tract disease caused by RSV in individuals 18-59 years of age who are at increased risk for disease. This approval expands the previous indication of mRESVIA, which was approved in May 2024 for adults aged 60 years and older. hile the risk of RSV is well recognized in infants and older adult populations, adults aged 18-59 years with chronic conditions are also vulnerable.1 Over one-third of adults aged 18-59 years have at least one underlying condition that puts them at increased risk of severe RSV disease, with disease burden and hospitalization rates in this population being comparable, or even exceeding, that observed in older adults. This approval was supported by results from Moderna's Phase 3 study, which evaluated the safety and immunogenicity of mRESVIA in adults aged 18-59 with underlying health conditions. The immune responses against both RSV-A and RSV-B met prespecified non-inferiority immunobridging criteria when compared to those observed in adults aged 60 years and older in the pivotal Phase 3, placebo-controlled safety and efficacy study. Comparable levels of neutralizing antibodies were observed across both the 18-49 and 50-59 age subgroups, supporting the vaccine's consistent immunogenicity profile in this at-risk, younger adult population. The vaccine was generally well-tolerated, and the most commonly reported solicited adverse reactions were injection site pain, fatigue, headache, myalgia and arthralgia. Moderna intends to have mRESVIA available for both younger adults at increased risk (ages 18-59) and older adults (ages 60+) in the U.S. for the 2025-2026 respiratory virus season.'
Yahoo
3 hours ago
- Yahoo
Novavax's COVID-Flu Combo Shot Shows Strong Immune Response
Novavax NVAX announced encouraging results from an initial cohort of a late-stage study evaluating its experimental COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates. Results showed that the CIC and flu vaccines generated 'robust immune responses' across three flu strains (H1N1, H3N2 and B) and the SARS-CoV-2 strain in adults aged 65 and older. Per Novavax, these responses were similar to those seen with its own approved COVID-19 vaccine, Nuvaxovid, and Sanofi's SNY influenza vaccine, Fluzone HD. Novavax emphasized that this study was not designed to demonstrate statistical significance but to provide preliminary immunogenicity data. It intends to use these findings to design another late-stage study, which could potentially support regulatory submissions, if successful. NVAX is also exploring strategic collaborations to finance further development and potential commercialization of both candidates. This is part of the company's recent strategic shift focused on expanding its pipeline and exploring partnership opportunities for the same. Shares of Novavax have underperformed the industry year to date, as seen in the chart below. Image Source: Zacks Investment Research The above announcement came just under a month after it received the long-awaited FDA approval for Nuvaxovid, albeit with a narrower label than initially expected. While the agency granted full approval to the vaccine for use in older adults aged 65 and above, it restricted the use in individuals aged 12-64 with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19. This latest approval aligns with the FDA's recently issued guidance for COVID-19 vaccine boosters. As part of this guidance, COVID vaccine makers will be required to conduct randomized, placebo-controlled clinical studies demonstrating the real-world benefit of yearly COVID vaccine boosters in individuals aged under 65 years. Starting this year, Sanofi has acquired exclusive rights to market Nuvaxovid globally, except in certain territories where Novavax maintains existing partnership agreements. This arrangement is part of a multi-billion-dollar deal signed last year, wherein Sanofi assumed commercial responsibility for the vaccine. The company is also eligible for ongoing tiered royalties on future sales of COVID-19 vaccines. Apart from Novavax, Pfizer PFE and Moderna MRNA are also developing their respective COVID/flu combination vaccines using mRNA technology. Despite the recent regulatory setback, Moderna remains ahead of its competitors with the development of its investigational COVID-19/flu vaccine candidate, mRNA-1083. Moderna had to voluntarily withdraw its FDA filing for mRNA-1083 to accommodate the agency's request for additional efficacy data on the flu component of the vaccine. Moderna intends to resubmit the filing later this year. Pfizer suffered a major setback in this space last year when it reported data from a phase III study on its investigational mRNA-based COVID-19/flu combination vaccine. The study missed one of its two primary immunogenicity objectives. Pfizer is currently evaluating adjustments to its combination vaccine program to improve immune responses against influenza B and plans to discuss the next steps with health authorities. Pfizer is developing this vaccine in collaboration with BioNTech. Novavax's deal with Sanofi also allows the latter to combine its own influenza vaccines with Nuvaxovid. Sanofi is currently testing multiple COVID-19/flu combination vaccine candidates under this arrangement. Last year, the FDA granted fast-track designation to two of Sanofi's experimental combination vaccines, both being evaluated in separate phase I/II studies. While the first combination uses the Fluzone HD vaccine with Nuvaxovid, the second pairs Novavax's COVID-19 shot with Flubok. Novavax, Inc. price | Novavax, Inc. Quote Novavax currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Moderna, Inc. (MRNA) : Free Stock Analysis Report Novavax, Inc. (NVAX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research